leisure time -WSS

leisure time

author：comprehensive 2025-10-02 08:32:26 - browse：369

Sammy Kimball for STAT

Is Wegovy really a brain drug? Which Alzheimer’s disease treatment works best? And what’s the point of Threads?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Megan Molteni joins us to explain the evolving science suggesting products like Wegovy are less weight loss drugs than treatments for human desire. We also explain why this summer is shaping up to be a pivotal moment for the treatment of Alzheimer’s and discuss our befuddlement with the latest social media platform.

For more on what we cover, here’s the story on GLP-1 drugs and the brain; here’s the latest on Leqembi; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Medicare has a new plan to address drug shortages

WSS

Why health workers in Gaza are injured or die at high rates

Key House panel plots a new health care package

Eli Lilly expects to double planned employment in Boston center

Lawmakers consider Medicare pay reforms for doctors

Custom gene therapy hints at new path for rare disease treatments

Doctors find melanoma drugs effective against rare brain cancer

knowledge

leisure time

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Sports medicine is finally prioritizing gender equality

Group opposing PBM reform sets lobbying record

The cancer drug shortage isn’t new — and neither are the solutions

Doctors find melanoma drugs effective against rare brain cancer

Medicare details structure of new drug price negotiation program

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

A public scorecard can help hold safety

focus

Pharmacists can make shortage drugs, but at what cost?

STAT Readout Newsletter: Today's biggest biotech updates

STAT Summit: Michael J. Fox on progress in Parkinson's research

Impact of Dobbs ruling felt at reproductive medicine meeting

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

FDA approves RSV monoclonal antibody for infants, toddlers

leisure time

knowledge

focus

entertainment